The bone mineral measurement core is necessary for the measurement of bone mass in both humans and in animals. The core has served the past two SCOR applications and has proven to be a cost effective mechanism of providing high precision measurements for 4 of the 5 projects proposed in this application. In Project 1, the vertebrae and femur of 24 transgenic mice will be measured in year 4. This core will be used to evaluate bone mass changes in mice and the excised bones from rats. In vivo measurements of L4-L6 vertebrae and the femur will be made 3 times per year in 80 live mice per year over the course of the experiment. Ex vivo samples of the femur and vertebrae in 65 rats each year will be measured by utilizing the DXA. Total sample measurements per year will be 580 scans. In Project 4, the cohort of 89 women with primary hyperparathyroidism will have bone mineral measurements at 3 skeletal sites (spine, hip, forearm) every 12 months to determine longitudinal changes in bone mass with medical treatment and following parathyroidectomy (total number of scans is 1068).This core will be used to compare the bone density response to hPTH 1-34 in estrogen deficient women, women on estrogen therapy and women in estrogen and placebo control groups. The bone density response to discontinuation and a later rechallenge of hPTH 1-34 will also be measured. Project 6 involves serial bone density measures (duplicate scans at baseline and every 6 months) at 5 skeletal sites (lumbar spine, hip, forearm, total body, and lateral spine) during the treatment, its' withdrawal and a later rechallenge. The total number of scans for all protocols in Project 6 is 4900. We have also incorporated into the core a feasibility study to determine whether micro-MRI can provide information equivalent to conventional histomorphometry and further improve the ability of bone mass to predict bone strength in the animal model. In addition to providing core support for the individual projects in this grant, the core has also been integral to the success of other NIH funded studies, at no additional cost to the SCOR grant.

Project Start
2000-09-01
Project End
2001-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
13
Fiscal Year
2000
Total Cost
$139,707
Indirect Cost
Name
Helen Hayes Hospital
Department
Type
DUNS #
157119244
City
Menands
State
NY
Country
United States
Zip Code
12204
Ascenzi, Maria-Grazia; Liao, Vivian P; Lee, Brittany M et al. (2012) Parathyroid hormone treatment improves the cortical bone microstructure by improving the distribution of type I collagen in postmenopausal women with osteoporosis. J Bone Miner Res 27:702-12
Zhang, Hao; Doty, Stephen B; Hughes, Christine et al. (2007) Increased resorptive activity and accompanying morphological alterations in osteoclasts derived from the oim/oim mouse model of osteogenesis imperfecta. J Cell Biochem 102:1011-20
Dempster, David W; Hughes-Begos, Christine E; Plavetic-Chee, Katarina et al. (2005) Normal human osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are stimulated by PTH in the absence of osteoblasts. J Cell Biochem 95:139-48
Cosman, Felicia; Nieves, Jeri; Zion, Marsha et al. (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353:566-75
Iida-Klein, A; Lu, S Shou; Kapadia, R et al. (2005) Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice. J Endocrinol 186:549-57
Kurland, Etah S; Heller, Samantha L; Diamond, Beverly et al. (2004) The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 15:992-7
Kim, Chi Hyun; Takai, Erica; Zhou, Hua et al. (2003) Trabecular bone response to mechanical and parathyroid hormone stimulation: the role of mechanical microenvironment. J Bone Miner Res 18:2116-25
Rubin, Mishaela R; Bilezikian, John P (2003) New anabolic therapies in osteoporosis. Endocrinol Metab Clin North Am 32:285-307
Zhou, H; Iida-Klein, A; Lu, S S et al. (2003) Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone 32:513-20
Dempster, David W (2003) The pathophysiology of bone loss. Clin Geriatr Med 19:259-70, v-vi

Showing the most recent 10 out of 125 publications